UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 112

Sortiert nach

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet (British edition), 2019-11, Vol.394 (10213), p.2012-2024

2019

Volltextzugriff (PDF)

Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

Hepatology (Baltimore, Md.), 2021-09, Vol.74 (3), p.1220-1233

2021

Volltextzugriff (PDF)

Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations

Hepatology (Baltimore, Md.), 2021-03, Vol.73 (3), p.1199-1206

2021

Volltextzugriff (PDF)

Disparities in liver transplantation before and after introduction of the MELD score

JAMA : the journal of the American Medical Association, 2008-11, Vol.300 (20), p.2371

2008

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C

Digestive diseases and sciences, 2021-07, Vol.66 (7), p.2394-2406

2021

Volltextzugriff (PDF)

Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease

Gastroenterology (New York, N.Y. 1943), 2013-11, Vol.145 (5), p.1076-1087

2013

Volltextzugriff (PDF)

Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease

Hepatology (Baltimore, Md.), 2014-02, Vol.59 (2), p.471-482

2014

Volltextzugriff (PDF)

Association Between Magnetic Resonance Imaging–Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

Gastroenterology (New York, N.Y. 1943), 2018-11, Vol.155 (5), p.1428-1435.e2

2018

Volltextzugriff (PDF)

1359-P: Gaps in the Use of Evidence-Based Diabetes Medications for NASH

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Volltextzugriff (PDF)

Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome

Frontiers in oncology, 2022-08, Vol.12

2022

Volltextzugriff (PDF)

Vibration-Controlled Transient Elastography for Diagnosing Cirrhosis and Staging Hepatic Fibrosis

JAMA : the journal of the American Medical Association, 2018-11, Vol.320 (19), p.2031

2018

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries

Journal of the American Heart Association, 2021-11, Vol.10 (22), p.e021654-e021654

2021

Volltextzugriff (PDF)

Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation

Digestive Diseases and Sciences, 2016-05, Vol.61 (5), p.1406-1416

2016

Volltextzugriff (PDF)

Hedgehog Controls Hepatic Stellate Cell Fate by Regulating Metabolism

Gastroenterology (New York, N.Y. 1943), 2012-11, Vol.143 (5), p.1319-1329.e11

2012

Volltextzugriff (PDF)

Leptin Promotes the Myofibroblastic Phenotype in Hepatic Stellate Cells by Activating the Hedgehog Pathway

The Journal of biological chemistry, 2010-11, Vol.285 (47), p.36551-36560

2010

Volltextzugriff (PDF)

Introduction to the Nonalcoholic Fatty Liver Disease Special Issue

Clinical liver disease (Malden, Mass.), 2021-01, Vol.17 (1), p.1-1

Moylan, Cynthia A.

2021

Volltextzugriff (PDF)

Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes

Endocrine practice, 2024-07, Vol.30 (7), p.663-669

2024

Volltextzugriff (PDF)

Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease

Journal of hepatology, 2021-09, Vol.75 (3), p.623-633

2021

Volltextzugriff (PDF)

Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis

The American journal of gastroenterology, 2016-11, Vol.111 (11), p.1591-1598

2016

Volltextzugriff (PDF)

S1440 Higher Household Dysfunction in Adverse Childhood Experiences Score & Low Household Income Associate With Increased Risk of Cirrhosis in Adulthood

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S1097-S1098

2023

Volltextzugriff (PDF)

Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis

American journal of physiology: Gastrointestinal and liver physiology, 2009-12, Vol.297 (6), p.G1093-G1106

2009

Volltextzugriff (PDF)

Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study

PloS one, 2018-09, Vol.13 (9), p.e0204308-e0204308

2018

Volltextzugriff (PDF)

Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

Hepatology (Baltimore, Md.), 2018-10, Vol.68 (4), p.1646-1648

2018

Volltextzugriff (PDF)

Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration

Digestive diseases and sciences, 2018-09, Vol.63 (9), p.2259-2266

2018

Volltextzugriff (PDF)

Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression

Cellular and molecular gastroenterology and hepatology, 2020-01, Vol.10 (1), p.1-21

2020

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(99)

Publikationsform

Artikel
(112)

Sprache

Englisch
(112)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease

Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations

Disparities in liver transplantation before and after introduction of the MELD score

Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C

Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease

Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease

Association Between Magnetic Resonance Imaging–Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

1359-P: Gaps in the Use of Evidence-Based Diabetes Medications for NASH

Racial disparities in liver cancer: Evidence for a role of environmental contaminants and the epigenome

Vibration-Controlled Transient Elastography for Diagnosing Cirrhosis and Staging Hepatic Fibrosis

Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries

Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation

Hedgehog Controls Hepatic Stellate Cell Fate by Regulating Metabolism

Leptin Promotes the Myofibroblastic Phenotype in Hepatic Stellate Cells by Activating the Hedgehog Pathway

Introduction to the Nonalcoholic Fatty Liver Disease Special Issue

Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes

Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease

Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis

S1440 Higher Household Dysfunction in Adverse Childhood Experiences Score & Low Household Income Associate With Increased Risk of Cirrhosis in Adulthood

Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis

Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study

Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis

Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration

Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression

Suchergebnisse filtern